神经病理性疼痛（NP）患病率高。目前认为其形成机制主要是以脊髓长时程增强（LTP）效应为核心的中枢敏化，西药临床疗效不理想。具有通郁散结功效的升降散治疗NP疗效较好，符合中医"通则不痛"的治疗理念，现代研究提示升降散有抗炎、抗血小板聚集、抑制神经兴奋性抗惊厥等作用，但其治疗NP的机制研究甚少。对于疼痛，西医却认为"痛则通，不通则不痛"，这两种理念是相互矛盾？还是两种理论体系的不同表述？为此，本项目结合既往有关升降散药理药效学研究结果的提示，采取周围神经损伤性NP动物模型，通过观察升降散对损伤侧C纤维诱发脊髓背角LTP电位的影响，以及对脊髓炎性介质TNF-α、IL-6、P-38MAPK基因及蛋白表达的影响，对在血小板聚集和NP形成过程中均起作用的P2Y12受体的影响，对兴奋性神经递质NMDA及其受体和抑制性神经递质GABA及其受体的调节作用，探讨升降散治疗NP的机制，阐释"通则不痛"的机理。

Neuropathic pain ( NP ) have high prevalence rate, to the patient's daily life brought great suffering. The present study suggest that the formation mechanism is mainly because of the central sensitization to spinal LTP as the core, The clinical curative effect of Western medicine is not ideal. Shengjiang Powder have the effect of poking and eliminating stagnation,and have good effect in the treatment of NP. It In accordance with the Chinese medicine treatment concept of "no block no pain". modern research suggests Shengjiang Powder has anti-inflammatory, anti-platelet aggregation, inhibition of excitatory neural anticonvulsive effect, but its mechanism study on the treatment of NP little. For pain, Western medicine consider "Pain is pass,no pass no pain", these two ideas are contradictory? Or different expressions of two theoretical systems? Therefore, the project combines the hint of previous research results, adopt the animal experiment of peripheral nerve injury NP model, by observing the effect of Shengjiang Powder on the injury side C fiber evoked spinal dorsal horn of spinal cord LTP potential, and its influence on the gene and protein expression of inflammatory mediators of TNF- α, IL-6, P-38 MAPK, its influence on the expression of P2Y12 receptor,and its moderating effect on the excitatory neurotransmitter NMDA and its receptor and the inhibitory neurotransmitter GABA and its receptor, investigate Shengjiang Powder Treatment Mechanism of NP, explains the mechanism of "no block no pain"